Search Results 1271-1280 of 19025 for Neutrophil

1. A Study to Evaluate the Safety and Tolerability of DCC-2618 in Patients with Advanced Malignancies - Mayo Clinic

   Solid Tumor Patients: Bone Marrow Function; Absolute neutrophil count (ANC) ≥ 1500/µL; Hemoglobin ≥ 9 g/dL; Platelet count ≥ 75,000/µL. All Patients ...

2. Hidradenitis suppurativa - Doctors and departments - Mayo Clinic

   ... Neutrophilic dermatoses. Show more areas of focus for Anagha Bangalore Kumar, M.B.B.S.. Stella X. Chen, M.D.. Dermatologist. Phoenix, AZ ...

3. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma - Mayo Clinic

   Absolute Neutrophil Count (ANC) <1500/mm³. Must have Stage III or Stage IV disease. Baseline measurements/evaluations obtained within 6 weeks of registration ...

4. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Absolute neutrophil count (ANC) < 1.5 x 10^9 /L (< 1500/mm^3);; Platelet count < 100 x 10^9 /L (< 100,000/mm^3 );; < eGFR < 60 mL/min/1.73 m^2 using SCr or ...

5. CSF1R And TAM Receptor Inhibition With Q702 - Mayo Clinic

   Absolute neutrophil count (ANC) ≥1.0 x 109/L. Platelet count ≥80 x 109/L. WBC ≥2.5 x 109/L. Total bilirubin ≤1.5 x ULN. Alanine aminotransferase (ALT) ...

6. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/μL (1.5 x 10^9/L);; Platelet count ≥ 100 x10^9/L. Have an Eastern Cooperative Oncology Group (ECOG) performance ...

7. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L. Platelets ≥ 100 x 10^9/L. Hemoglobin ≥ 9.0 g/dL or 5.6 mmol/L. International normalized ratio (INR) or ...

8. Niraparib + TSR042 In BRCA Mutated Breast Cancer - Mayo Clinic

   - Absolute neutrophil count (ANC) ≥ 1500/mm3 - Platelet count ≥ 100,000/mm3 - Hemoglobin ≥ 9 g/dl - Total serum bilirubin ≤ 1.5 × institutional upper ...

9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Hematologic: Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without platelet transfusion or any growth ...

10. A Phase I, Multi-Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with AG120 or Pemigatinib for Advanced Cholangiocarcinoma - Mayo Clinic

    Absolute neutrophil count ≥ 1,500/mm^3 (obtained ≤ 21 days prior to registration). Platelet count ≥ 100,000/mm^3 (obtained ≤ 21 days prior to ...